Juan Gómez Rivas, Associate Professor at Complutense University of Madrid, shared a post on X:
“A productive weekend working on PIONEER and real-world data in localized prostate cancer.
We used the study-a-thon to define a focused research portfolio using broad real-world datasets: baseline characteristics, first-line treatment, subsequent treatment, metastasis after primary therapy, adverse events, and overall survival.
The potential research lines include treatment patterns, disease trajectory, outcomes in elderly and frail patients, post-primary treatment sequencing, adverse-event burden, and long-term survivorship.
We also aligned on key endpoints: metastasis-free survival, ADT-free survival, local-treatment-free survival, time to first subsequent local or systemic treatment, and overall survival.
Most excitingly, we have identified more than 500,000 patients with localized prostate cancer across our datasets.
But beyond the numbers, this weekend was also a reminder that bringing the right people together, clinicians, researchers, data scientists, and collaborators, is what turns ideas into projects and projects into impact.
This is a huge opportunity to generate meaningful real-world evidence in prostate cancer.
Big data is coming, stay tuned.”
Other articles featuring Juan Gómez Rivas on OncoDaily.
